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Tuberculosis, historically one of the deadliest and most
prevalent infectious diseases, is caused by the bacterium
Mycobacterium tuberculosis. It is estimated that one-third of
the world’s population is infected by this agent (Zumla et al.,
2014), and tuberculosis is therefore a major topic for medical
students. M. tuberculosis is a small aerobic bacillus, with a
remarkably high lipid-content cell wall that plays a critical role
in its pathogenicity. Although the efﬁcacy of the Bacillus
Calmette-Guérin (BCG) vaccine for preventing tuberculosis
continues to be debated (Villarreal-Ramos, 2009), live
attenuated BCG has been the only approved vaccine
against M. tuberculosis infection since its introduction in
1921, and is still administered routinely around the world,
particularly in developing countries. In China, BCG has been
included in the national vaccination program for newborns
and children under 15 since the mid-1970s. After decades of
intensive effort, remarkable progress has been made in the
ﬁght against tuberculosis in China. This great achievement
was made possible by Liang Wang, a physician who pio-
neered the introduction of the BCG vaccine to China in the
early 1930s and spearheaded China’s ﬁght against tuber-
culosis (Yan, 2003; Dai et al., 2014).
Although his accomplishments are frequently discussed
in the medical school classroom, most students are unfa-
miliar with Liang Wang’s personal story and the signiﬁcant
challenges he faced in his battle against tuberculosis. Liang
Wang was born on May 5, 1891 in Chengdu in the Sichuan
Province. He lost his father at very young age. After gradu-
ating from the Hanoi Medical School in Vietnam in 1913, he
entered private practice in the Yunnan and Sichuan regions
of China. In the early 20th century, tuberculosis was the
leading cause of death. Because there was no known cure,
the severe health threat posed by tuberculosis was consid-
ered to be as serious as that posed by cancer today. Wang’s
older brother and younger sister both died of tuberculosis. As
a young doctor, Liang Wang determined to devote himself
completely to the ﬁght against tuberculosis.
In 1924, Albert Calmette and Camille Guérin from the
Pasteur Institute in France published their research results
on the BCG vaccine, demonstrating its efﬁcacy in the pre-
vention of tuberculosis. One year later, Liang Wang learned
about BCG and began fundraising to support a trip to
France. With the help of France’s foreign ministry, Wang was
able to visit the Pasteur Institute in 1931, where he began his
research career under the personal guidance of Guérin.
Wang’s modesty and eagerness to learn were quickly
appreciated. During his two years at the Pasteur, Wang
completed four research papers, three of which focused on
BCG and the culture of M. tuberculosis. In the summer 1933,
Liang Wang returned to China with the BCG seed strain and
lab equipment. He established a microbiology laboratory
while working as a physician in a private hospital in
Chongqing. He committed much of his spare time to BCG
culture preparation and developed the ﬁrst batch of BCG
vaccine in China. Beginning October 1933 through August
1935, 248 infants were inoculated with the BCG vaccine
manufactured by Liang Wang. No adverse reactions were
observed. Crucially, BCG vaccination conferred signiﬁcant
protection against the development of tuberculosis, and also
offered some degree of immunity against other common
infectious diseases.
However, just as Liang Wang was planning to expand and
promote BCG vaccination, the Japanese invaded China in
1937, beginning the Anti-Japanese War, also known as the
Second Sino-Japanese War. Wang’s lab was forced to close,
and the development of the vaccination project halted for
more than a decade until the Japanese were defeated and
the People’s Republic of China was established.
The new Department of Health, opened by the Southwest
Military Administrative Committee in Chongqing, provided
Liang Wang with the opportunity continuing his work. He was
invited to participate in the ﬁrst national health working
conference in 1950, and was authorized by the central
government to found the Southwest Chinese BCG
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Production and Research Institute in Chongqing under his
leadership. Beginning August 1951, the health ministry held
three training classes to promote the use of Wang’s BCG
vaccine, and BCG vaccination quickly became popularized.
In 1956, the Southwest BCG Production and Research
Institute was incorporated into the Chengdu Institute of
Biological Products (Fig. 1), where Liang Wang devoted the
later stages of his professional career to BCG research and
manufacturing.
For the next 30 years, Wang insisted on the priority of
clinical application and the principle of combining theory with
practice. By focusing on three speciﬁc areas of research, he
contributed signiﬁcantly to the reﬁnement of BCG-based
immunization strategies to control tuberculosis in China.
First, Wang emphasized the improvement of BCG vac-
cine quality. Wang optimized the chemical composition of
BCG by decreasing the content of monosodium glutamate
from 8% to 6% and glycerol from 6% to 5%, making it more
suitable for live attenuated BCG. He also determined the
most effective concentration of sucrose (8%) for the pro-
tection of lyophilized BCG preparations by using the opti-
mum seeking method. To determine the shelf life for the
vaccine, Wang measured the loss in potency for 10 different
batches of BCG vaccine after storage at 4°C for 6 weeks,
and conﬁrmed that 26% of bacteria remained viable, a level
sufﬁcient to induce the body’s immune response.
Second, Wang began a process to isolate a superior BCG
strain for vaccine production. Due to different passage
methods and culture conditions, the BCG vaccine used in
different countries varied. In collaboration with others, both
locally and nationally, Liang Wang performed a two-year-
long BCG breeding program in which he compared a large
number of domestic and international BCG strains and
established efﬁcient detection protocols. His achievements
provided the experimental basis for the selection of the
Shanghai D2 strain from Denmark as the foundation for BCG
vaccine production.
Third, Wang actively investigated the immunologic
mechanisms underlying BCG efﬁcacy. In an analysis of
various blood constituents in BCG-immunized animals, he
observed that the number of leukocytes increased
signiﬁcantly 3 days after vaccination, peaked on day 5, and
returned to normal on day 12. Lymphocytes were the most
markedly increased cell type. Through many experiments,
he determined that the cytophagic capacity of reticuloen-
dothelial cells and phagocytes were remarkably enhanced in
BCG-vaccinated animals, and serum immunoglobulins were
also signiﬁcantly elevated. Wang also noted that the pro-
tection conferred by BCG vaccination persists even after
allergies have disappeared in immunized animals. His work
demonstrated that BCG induces not only cell-mediated
immunity but also humoral immunity, consistent with the non-
speciﬁc immunity observed in infants enrolled in Wang’s ﬁrst
vaccination project in 1935. Furthermore, Wang also found
that BCG-immunized animals exhibited an enhanced ability
to resist infection caused by Staphylococcus aureus and
other species from the genus Salmonella and Streptococ-
cus. This remarkable discovery provided the foundation for
the clinical application of BCG and its active ingredients as
immunological treatments for cancer and other diseases,
and deﬁned the future direction for development of a series
of therapeutic BCG-associated products.
With his strong work ethic and rigorous attitude
toward research, Liang Wang devoted himself wholeheart-
edly to his anti-tuberculosis career. He was invariably cour-
teous, amiable, and easy to approach, and paid close
attention to the cultivation of young scientists and physi-
cians. He remained active as a writer and lecturer even
when nearly 90 years old. In 1983, an academic symposium
was organized by the Chengdu Institute of Biological Prod-
ucts to celebrate the 50th anniversary of Wang’s profes-
sional career and his 92th birthday.
On August 31, 1985, Liang Wang died at the age of 94 in
his hometown of Chengdu.
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Figure 1. The Chengdu Institute of Biological Products in
its early days.
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